About us.
Find out how we’re transforming ideas into impact at scale through the businesses we identify, back and grow.
Our portfolio.
Investors.
We have a proven track-record in backing and nurturing science and technology-based businesses to deliver a better future for people and planet.
Our impact.
Find out how we’re living our purpose and identifying, backing and growing businesses that contribute to a healthier, tech-enriched, sustainable future.
News & Events.
Open and close mobile menu
IP Group news
16 Jun 2026
Portfolio company Istesso starts Phase 2 clinical trial of leramistat in sarcopenia
IP Group plc
12 May 2026
Portfolio company Enterprise Therapeutics reports positive results from Phase 2 clinical trial for cystic fibrosis
07 May 2026
Appointment of Michael Queen as Chair Designate
Portfolio news
Istesso initiates Phase 2 clinical trial of leramistat in sarcopenia
Istesso Ltd
08 Jun 2026
France doubles down on natural hydrogen as Mantle8 secures exclusive Pyrenees permit
Mantle8
Robust Phase 2b efficacy and favorable tolerability support monthly dosing for Pfizer’s GLP-1 RA Berobenatide
Pfizer obesity royalty interest
11 Dec 2025
07 Nov 2025
18
Hybrid
Event has passed
17
Virtual
